The second federal bellwether trial over transvaginal mesh devices has settled for an undisclosed sum, while manufacturer C.R. Bard Inc. continues to press that the FDA’s approval of its device should be admitted as evidence to jurors.
The settlement was revealed in a filing on Friday by U.S. District Judge Joseph Goodwin, who is overseeing litigation over transvaginal mesh products in Charleston, W.Va. A separate federal jury in the first bellwether trial awarded $2 million to a woman who alleged that Bard failed to warn of defects in its product that caused her bleeding and pain.
